I Lomares Manzano
YOU?
Author Swipe
View article: Reproducible GIS-Based Evidence for Public Health and Urban Security: A Systematic Mapping and Review
Reproducible GIS-Based Evidence for Public Health and Urban Security: A Systematic Mapping and Review Open
Geographic Information Systems (GIS) have consolidated as essential analytical tools for addressing public health and urban security challenges, yet the available evidence remains fragmented due to methodological heterogeneity and geograph…
View article: Exploring Components, Sensors, and Techniques for Cancer Detection via eNose Technology: A Systematic Review
Exploring Components, Sensors, and Techniques for Cancer Detection via eNose Technology: A Systematic Review Open
This paper offers a systematic review of advancements in electronic nose technologies for early cancer detection with a particular focus on the detection and analysis of volatile organic compounds present in biomarkers such as breath, urin…
View article: 4CPS-101 Biologic agents in rheumatological diseases: impact of ‘treat to target’ in clinical practice
4CPS-101 Biologic agents in rheumatological diseases: impact of ‘treat to target’ in clinical practice Open
Background and importance The aim of rheumatological diseases (RD) treatment should be clinical remission (CR) or alternatively a state of low level of clinical activity. The treatment of RD with a 'treat to target' (T2T) strategy consists…
View article: 4CPS-107 Immunotherapy in severe uncontrolled asthma: effectiveness and safety in clinical practice
4CPS-107 Immunotherapy in severe uncontrolled asthma: effectiveness and safety in clinical practice Open
Background and importance Immunotherapy is used in those patients with severe uncontrolled asthma (SUA) despite treatment with inhaled glucocorticoids (IGC) and beta2 adrenergic agonists (LABA) at high doses, and/or oral glucocorticoids (O…
View article: 4CPS-092 Biological therapies for the treatment of psoriasis: effectiveness, safety and economic impact of optimisation strategies
4CPS-092 Biological therapies for the treatment of psoriasis: effectiveness, safety and economic impact of optimisation strategies Open
Background and importance The goal of psoriasis treatment is to achieve and maintain the widest possible clearance of lesions and control of systemic inflammation over the long term. Biological therapies (BT) are only indicated moderate-se…
View article: 5PSQ-160 Mogamulizumab experience in advanced Sezary syndrome: a case report
5PSQ-160 Mogamulizumab experience in advanced Sezary syndrome: a case report Open
Background and importance Sezary syndrome (SS) is a primary cutaneous T cell lymphoma characterised by erythroderma, lymphadenopathy and leukaemic involvement of the peripheral blood. The high relapse rates and poor prognosis complicate it…
View article: 5PSQ-169 Safety and severe neutropenia in patients treated with palbociclib and ribociclib in real world clinical practice
5PSQ-169 Safety and severe neutropenia in patients treated with palbociclib and ribociclib in real world clinical practice Open
Background and importance Palbociclib and ribociclib are oral inhibitors of cyclin dependent kinases for firstline and secondline treatment of hormone receptor (HR) positive, HER2 negative locally advanced or metastatic breast cancer (BC).…
View article: 4CPS-348 The hospital pharmacy in the creation of clean circuits in the face of COVID-19
4CPS-348 The hospital pharmacy in the creation of clean circuits in the face of COVID-19 Open
Background and importance The SARS-CoV-2 health crisis unleashed in Spain in March 2020 forced hospitals to urgently reorganise and adapt in an unprecedented way. One of the strategies carried out was the establishment of 'clean' circuits …
View article: 4CPS-087 Optimisation of resources in the use of immunotherapy: nivolumab and pembrolizumab weight based dosing instead of flat dose
4CPS-087 Optimisation of resources in the use of immunotherapy: nivolumab and pembrolizumab weight based dosing instead of flat dose Open
Background and importance Nivolumab and pembrolizumab are highly selective blockers of anti-programmed death-1 (PD-1). Nivolumab was authorised to be administered in weight based dosing (WBD) schedules at 3 mg/kg every 2 weeks (w) for all …